A complementary DNA for a glucagon-like peptide-1 receptor was isolated from a human pancreatic islet cDNA library. The isolated clone encoded a protein with 90% identity to the rat receptor. In stably transfected fibroblasts, the receptor bound I n normal individuals, oral glucose absorption induces a greater insulin secretory response than an isoglycemic intravenous glucose infusion. This greater effect of oral glucose results from the secretion of intestinal hormones, which, at the level of the pancreatic p-cells, potentiate glucose-induced insulin secretion (1,2). These
hormones are thus referred to as glucoincretins. The two main glucoincretins characterized so far are GIP and GLP-1 (3) (4) (5) . GLP-1 is generated in intestinal L-cells by a cell-specific proteolytic cleavage of the preproglucagon molecule (6) . This hormone is a glucoincretin in both rats and humans (1, 3, 7) . Importantly, the stimulatory action of GLP-1 on insulin secretion requires the presence of glucose at normal or slightly elevated concentration and is mediated by elevation in intracellular cAMP (8, 9) . In addition to its stimulatory effect on secretion, GLP-1 also stimulates insulin gene transcription (9) .
In diabetes, the total incretin effect is markedly reduced (1). This, however, does not result from a decreased secretion of GLP-1 or of GIP because normal or even elevated circulating levels of these hormones have been found in NIDDM patients (10) (11) (12) . Therefore, the decreased incretin effect may be caused by a deficient action of these hormones at the p-cell level, either as a result of decreased receptor number or because of defects in intracellular signal transduction. However, recent studies have shown that infusion of pharmacological doses of GLP-1, but not of GIP, could ameliorate postprandial glucose levels by stimulating insulin secretion in diabetic patients (10, 13, 14) . Because GLP-1 insulinotropic action is glucose dependent, this peptide or agonists of its receptor could be used as new antidiabetic agents without the risk of inducing hypoglycemia, a complication often encountered with the currently used antidiabetic sulfonylureas (15) .
The possible therapeutic use in NIDDM of GLP-1 receptor agonists stresses the need for the characterization of the human GLP-1 receptor. We report herein the characterization by molecular cloning and functional expression of a human pancreatic islet's GLP-1 receptor. Moreover, we demonstrate that two peptides of related structure, exendin-4 and exendin-(9-39) (16) , are agonists and antagonists of the receptor, respectively. This will help characterize the receptor binding site and may be an important step in the design of new antidiabetic drugs acting through the GLP-1 receptor.
RESEARCH DESIGN AND METHODS Library construction and screening.
A human pancreatic islet cDNA library constructed in \-gt11 (17) (gift of Mike M. Mueckler, Saint Louis, MO) was screened with a 1.12-kb Kpn\-Pst\ fragment derived from the pGLPR-1 plasmid, which contains a full-length rat GLP-1 receptor cDNA (18) . The probe was labeled by random priming (19) and hybridization was performed at reduced stringency: 30% formamide, 5 x SSC (1 x SSC: 150 mM NaCI, 15 mM Na3 citrate, pH 7.0), 0.2% SDS, 5 x Denhardt (1 x Denhardt: 0.2 g/L BSA, 0.2 g/L polyvinylpyrrolidone, 0.2 g/L Ficoll), 50 mM sodium phosphate, pH 6.8, 5 mM EDTA, and 100 ug/ml salmon sperm DNA, at 42°C for 18 h. Washings were done 4 times for 20 min in 2 x SSC, 0.2% SDS at 42°C. The filters were then exposed with an intensifier screen to Kodak XAR-5 films at -70°C. Positive clones were purified by two or three additional cycles of screening in the same conditions. A second human islet cDNA library was constructed as follows. Human islets purified by the method of Ricordi et al. (20, 21) were used to prepare polyA RNA by the method of Gonda et al. (22) . Double-stranded cDNAs were prepared from 4 \ig of polyA RNA and sizeselected according to Aruffo and Seed (23) , as described previously (18) . cDNA with sizes >1.6 kb were pooled and ligated in EcoRI-cut X-ZAP II (Stratagene, La Jolla, CA). The ligation reaction was used for packaging with GigaPack Gold extracts (Stratagene). The phages were then grown on a lawn of XL1 -Blue bacteria. Screening of the unamplified library (5.10 5 independent plaque forming units) was performed with the partial clone obtain from the \-gt11 library as a probe. Inserts of plaquepurified phages were excised into Bluescript SK(-) by superinfection with the helper phage R408 (Stratagene), as per the manufacturer's protocol. DNA sequencing and analysis. Sequencing of the cDNA inserts was performed on double-stranded DNA by the chain termination technique (24) with Sequenase (U.S. Biochemical, Cleveland, OH) using synthetic primers derived from the deduced nucleotide sequence and buffer gradient gel electrophoresis (25) . CA) or Bachem (Torrence, CA) except exendin-4 and exendin-(9-39), which were gifts from Dr. John Eng (VA Medical Center, Bronx, NY), lodination of GLP-1 was performed as described previously (18). cAMP assay. Cells plated in 12-well plates were loaded with 2 mCi tritiated adenine (TRK311, Amersham, Amersham, UK) for 5 h at 37°C. Stimulation with peptides at different concentrations or with 100 mM forskolin was for 8-15 min at 37°C in the presence of 1 mM IBMX. After removal of the medium, cells were lysed with 1 ml of 5% trichloroacetic acid containing 0.1 mM cAMP and 0.1 mM ATP, and the intracellular tritiated cAMP was separated on Sephadex and alumina columns as described previously (26) .
RESULTS
Screening of a human \-gt11 cDNA library was performed with the rat GLP-1 receptor cDNA (18) . A single clone with high (83%) nucleotide sequence identity to the rat receptor was isolated. This cDNA clone (hGLPR-20) (Fig. 1 ) contained only part of the coding region, from nucleotide 689 to the translation termination codon, plus the entire 3'-untranslated region. No other clones for this receptor could be found in this library. A new human islet cDNA library was therefore constructed in the X-ZAP II vector and screened at high stringency with clone hGLPR-20. One clone (hGLPR-6 [20] ) (Fig. 1 ) contained a cDNA coding for a full-length GLP-1 receptor. The deduced amino acid sequence was 90% identical and 96% homologous to the rat receptor (18) (Fig. 2) . The cDNA clone hGLPR-6(20) has, in the 3'-untranslated region, a nucleotide sequence not found in clone hGLPR-20 ( Fig.  1 ) and that contains a dinucleotide (CA)18 repeat. This segment may be an intronic sequence that was part of an incompletely spliced mRNA. The boundaries of this sequence indeed conform to the canonical nucleotide sequences bordering the end of introns (26) (Fig. 1) . However, the same dinucleotide repeat was found at a similar location in the three previously cloned rat GLP-1 receptor cDNAs (18) . Therefore, the presence of this CA repeat in the 3'-untranslated region may be part of, and of functional significance, for the mature receptor mRNA. This region of the receptor mRNA is, however, less conserved between human and rat (62% identity) compared with the nucleotide sequence of the coding region (86% identity). Northern blot analysis of islet polyA RNA with the cloned cDNA revealed the presence of a major 2.6-kb transcript and less abundant transcripts of 4.1, 5.0, and 6.0 kb (Fig. 3) . Hybridization of a blot containing 2 |xg of polyA RNA from human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas did not reveal the presence of any hybridizing bands. Chinese hamster fibroblasts (CHL cells) transfected with the receptor cDNA displayed high affinity binding sites for [
125 l]GLP-1(7-36) amide (Fig. 4) with a calculated K 6 of 0.5 nM. As for the rat receptor (18) , binding of iodinated GLP-1 could not be displaced by GIP, secretin, or VIP (not shown). Binding could be displaced by 70% by oxyntomodulin or by the extended form of GLP-1, GLP-1 (1-36)amide, but only when present at a concentration of 1 |xM (not shown). Interestingly, however, exendin-4 and exendin-(9-39) displaced radioiodinated GLP-1 binding with IC 50 s of 0.5 nM and 1.7 nM, respectively. These values were not significantly different from that of GLP-1.
Coupling of the receptor to adenylate cyclase was the expression vector alone (not shown). Exposure of receptor-transfected fibroblasts, but not of nontransfected CHL cells, to exendin-4 induced the production of cAMP with an EC 50 of -33 pM (11-to 12-fold maximal stimulation over basal). Exendin-(9-39) did not induce any detectable production of cAMP in transfected cells. Importantly however, exendin-(9-39) was able to dose dependently block the production of cAMP induced by GLP-1 (Fig. 6 ). Exendin-(9-39) is therefore an antagonist of the cloned human GLP-1 receptor.
DISCUSSION
Agonists of the GLP-1 receptor might be used as antidiabetic agents (11, 13, 14) . The present characterization of a human pancreatic islet's GLP-1 receptor is therefore of critical importance for the development of new therapeutic agents. Indeed, although highly homologous to the rat receptor (18) , the human receptor may display different binding properties for a putative nonpeptide agonist, as has been reported for the human and canine cholecystokinin-B/gastrin receptor (27) . Furthermore, we demonstrate that two peptides isolated from the venom of the lizard Heloderma suspectum, exendin-4 and exendin-(9-39) (16) , which show high sequence similarity to GLP-1, can bind the cloned human receptor with high affinity. In a previous report (28) , GLP-1 was shown to displace exendin-4 and exendin-(9-39) from their binding sites on pancreatic acini, suggesting that GLP-1 could bind to a receptor common to these peptides. The molecular nature of the pancreatic acini binding site was not identified. It may have been different from the cloned GLP-1 receptor because in humans (this report) and in rats (18) , no GLP-1 receptor mRNA could be detected by Northern blot analysis of total pancreas RNA, although it was abundant in Langerhans islets. Interestingly, whereas exendin-4 acted as an agonist of the receptor, exendin-(9-39) behaved as a perfect antagonist and was able to block GLP-1 -induced cAMP formation. Structurally, 7 of 8 amino terminal amino acids are identical between exendin-4 and GLP-1 (28) . On the remainder of the molecule, only 9 of 22 amino acids are conserved between exendin-4, exendin-(9-39), and GLP-1. This suggests that some residues in the COOH-terminal end of these peptides may be sufficient for binding but that agonist properties require the presence of the highly conserved 8 amino-terminal residues.
The glucoincretin effect is reduced in diabetic patients, probably because of a defect in binding or signaling by these hormones at the p-cell level (10) (11) (12) . A lack of or decreased glucoincretin effect by GLP-1 may be a cause in the development of diabetes. The presently described cDNA may therefore also help us understand the regulated expression of this receptor in the development of diabetes, and the identification of a microsatellite in the 3'-untranslated region of the cDNA may, if polymorphic, be used for genetic studies aimed at linking a defect in this gene with development of diabetes.
been deposited to GenBank with the accession number U01104.
